Product Details

Purity

Greater than 85% as determined by SDS-PAGE.

Target Names

MAGEA3

Uniprot No.

P43357

Research Area

Cancer

Alternative Names

Antigen MZ2 D ; Antigen MZ2-D; Cancer/testis antigen 1.3; Cancer/testis antigen family 1 member 3; CT1.3; HIP8; HYPD; MAGA3_HUMAN; MAGE 3 antigen; MAGE family member A3; MAGE-3 antigen; MAGE3; MAGEA3; MAGEA6; Melanoma antigen family A 3; Melanoma associated antigen 3; Melanoma-associated antigen 3; MGC1461

Species

Homo sapiens (Human)

Source

E.coli

Expression Region

1-314aa

Target Protein Sequence

MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQEAASSSSTLVEVTLGEVPAAESPDPPQSPQGASSLPTTMNYPLWSQSYEDSSNQEEEGPSTFPDLESEFQAALSRKVAELVHFLLLKYRAREPVTKAEMLGSVVGNWQYFFPVIFSKASSSLQLVFGIELMEVDPIGHLYIFATCLGLSYDGLLGDNQIMPKAGLLIIVLAIIAREGDCAPEEKIWEELSVLEVFEGREDSILGDPKKLLTQHFVQENYLEYRQVPGSDPACYEFLWGPRALVETSYVKVLHHMVKISGGPHISYPPLHEWVLREGEE
Note: The complete sequence may include tag sequence, target protein sequence, linker sequence and extra sequence that is translated with the protein sequence for the purpose(s) of secretion, stability, solubility, etc.
If the exact amino acid sequence of this recombinant protein is critical to your application, please explicitly request the full and complete sequence of this protein before ordering.

Mol. Weight

39.8 kDa

Protein Length

Full Length

Tag Info

N-terminal 10xHis-tagged and C-terminal Myc-tagged

Form

Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Buffer

Tris-based buffer,50% glycerol

Troubleshooting and FAQs

Protein FAQs

Storage Condition

Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.

Shelf Life

The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.

Lead Time

3-7 business days

Notes

Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Datasheet & COA

Please contact us to get it.

Description

Unlock the potential of our superior Recombinant Human MAGEA3 protein, specifically designed for cancer research applications. Produced in E. coli, this full-length protein (1-314aa) boasts both an N-terminal 10xHis-tag and a C-terminal Myc-tag, enabling streamlined purification and detection processes. With a purity greater than 85% as determined by SDS-PAGE, our MAGEA3 protein ensures reliability and consistency for your experiments.

Dive deeper into the study of melanoma-associated antigens and their implications in cancer biology using this exceptional recombinant protein. Available in liquid or lyophilized powder forms, our Recombinant Human MAGEA3 protein is a powerful tool to enhance your research efforts.

Target Background

Function

Activator of ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases that acts as a as repressor of autophagy. May enhance ubiquitin ligase activity of TRIM28 and stimulate p53/TP53 ubiquitination by TRIM28. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex. May play a role in embryonal development and tumor transformation or aspects of tumor progression. In vitro promotes cell viability in melanoma cell lines. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes.

Gene References into Functions

rapid drop (>50%) in blood level within 4 weeks of melanoma treatment associated with long-term response to therapy PMID: 27561960
the objective response rate was lower in this study than in other studies carried out in the same setting with the MAGE-A3 immunotherapeutic. Investigation of a gene signatures (GS) to predict clinical benefit to adjuvant MAGE-A3 immunotherapeutic treatment is ongoing in another melanoma study. PMID: 27502712
Administering autologous CD4(+) T cells that are genetically engineered to express an MHC class II-restricted antitumor TCR that targets MAGE-A3 can be used safely in the treatment of metastatic neoplasms. PMID: 28809608
MAGEA3 may be demethylated in MPNST and plexiform type neurofibroma in NF-1 patients PMID: 27422441
MAGEA3 was overexpressed in colorectal cancer tissue compared with healthy colon. MAGEA3 expression positively correlated with colorectal cancer progression. PMID: 27635108
Comparing the overall expression of CTAs, a decreased expression of all melanoma-associated antigens (MAGEs) post-treatment and a slightly increased expression of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) was visible. The simultaneous cytoplasmic and nuclear expression of pan-MAGE or MAGE-A3/A4 correlated with reduced treatment-failure-free-survival (TFFS). PMID: 27466502
MAGE-A3 expression is regulated epigenetically by promoter methylation, and that its expression contributes to gastric cell proliferation and drug sensitivity. PMID: 26868260
Progression free survival and levels of MAGE-A3 expression in non-small cell lung carcinoma patients with the three modes of acquired resistance are negatively correlated. PMID: 26612451
the crystal structures of MAGE-A3 and MAGE-A4 PMID: 26910052
MAGEA3/6 positivity was associated with significantly better disease-free survival. PMID: 25564441
Anticancer effects of adenovirus-mediated calreticulin and melanoma-associated antigen 3 expression on non-small cell lung cancer cells PMID: 25704851
our findings indicated that MAGE-A3 is a novel cancer stem cell antigen in bladder cancer PMID: 25031712
MAGE-A3 may serve as a potential prognostic marker for clear cell renal cell carcinoma PMID: 25120790
Study describes a widespread mechanism to suppress AMPK through its ubiquitination and degradation by the cancer-specific MAGE-A3/6-TRIM28 ubiquitin ligase. MAGE-A3 and MAGE-A6 are highly similar proteins normally expressed only in the male germline but frequently re-activated in human cancers. PMID: 25679763
MAGE proteins bind to KAP1, a gene repressor and ubiquitin E3 ligase which also binds KRAB domain containing zinc finger transcription factors (KZNFs), and MAGE expression may affect KZNF mediated gene regulation. PMID: 25107531
Study demonstrated that the expression of MAGE-A3/4 antigen might be a valuable prognostic factor regarding survival in patients with NSCLC. PMID: 24675493
Data indicate that MAGE3, Survivin and B-cell maturation antigen (BCMA) mRNA-pulsed dendritic cells (DCs) are capable of stimulating tumor-associated antigens (TAA)-specific T-cell responses in multiple myeloma (MM) patients. PMID: 23728352
Cells bearing either intermediate proteasome present peptides MAGE-A(3114-122) and MAGE-C2(42-50) as efficiently as cells equipped with the immunoproteasome. PMID: 22925930
High MAGE-3 gene expression is associated with metastases in hepatitis C virus patients complicated by hepatocellular carcinoma. PMID: 21452042
the expression of MAGE, as confirmed in the RT-PCR analysis, could be used as an alternative method for the early diagnosis of salivary gland tumours. PMID: 22498264
Report MAGEA1-A6 expression and MAGE A3 methylation in sputum suggests presence of lung cancer cells or precancerous cells. PMID: 22134685
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. PMID: 22323448
Data indicate the association of MAGE-A3 expression and poor prognosis in diffuse large B-cell lymphoma (DLBCL) patients. PMID: 22183072
MAGE-A3 gene may have a clinical relevance and important role as a risk factor in the development of acute myeloid leukemia PMID: 21804405
Expression of MAGE I proteins, MAGE-A3 or MAGE-C2, relieved repression of a reporter gene by ZNF382 and MAGE I expression relieved KAP1 mediated ID1 repression. PMID: 21876767
we found that the SSX4 and MAGE-A3 genes are frequently expressed in brain tumor cell lines PMID: 21347689
MAGE-A3 was detected in a significantly higher percentage of relapsed patients compared with newly diagnosed, establishing a novel correlation with progression of disease. PMID: 21565982
MAGE-A3, a cancer-testis antigen, plays an important role in the survival of multiple myeloma cells. PMID: 20015885
Primary tumors with and without lymph node metastases showed no significant differences in MAGE-A 3/4 (P=0.672) and NY-ESO-1 (P=0.444) expression PMID: 21556122
RT-PCR assays of MAGE-A3 and MAGE-A4 in blood of breast cancer (BC) patients may have prognostic and predictive implications, and they are promising specific tumor markers of BC PMID: 21264495
MAGE3 expression mediated by demethylation of MAGE3 promoter induce progression of non-small cell lung cancer. PMID: 21273595
Molecular upstaging of MAGE-A3 using rt-pcr was correlated with prognosis in melanoma patients PMID: 21135695
Report immunohistochemical expression of MAGE-A3 in renal oncocytoma and chromophobe renal cell carcinoma. PMID: 20591578
results showed that MAGE-A3 gene expression was frequent in NHL patients and decreased after effective chemotherapy, suggesting that MAGE-A3 can be used as a tumor marker for circulating lymphoma cells in patients with NHL. PMID: 20036422
Tumor-specific antigen MAGE may play a role in the occurrence and development of ovarian cancer and can be used as one of the important indicators for early diagnosis, efficacy evaluation and prognostic determination of ovarian cancer. PMID: 20423514
MAGE-A3/6 and NY-ESO-1 were expressed in 50.0% (66/132) and 18.2% (24/132) of non-small-cell lung carcinomas, respectively. PMID: 19795170
Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3 PMID: 12393675
This melanoma-associated marker was detected in melanoma cell lines. PMID: 12710945
first evidence that the naturally processed MAGE-3(271-279) can be isolated and identified from the tumor tissue of hepatocellular carcinoma patient PMID: 15885805
The newly identified MAGE-3(113)-peptide epitope is naturally processed and presented as the CTL epitope on MAGE-3-expressing GI cancer cells, indicating that anti-MAGE-3 immune targeting with the MAGE-3(113) peptide is a promising approach for treatment. PMID: 16446550
MAGE-A3 gene mRNA is expressed at the mRNA level in a proportion of human leukemias. PMID: 16806467
The promoter hypomethylation of MAGE-A1 and MAGE-A3 genes up-regulates their expression in colorectal carcinomas as well as in gastric cancers and might play a significant role in the development and progression of human colorectal carcinomas. PMID: 17007017
Gene expression profiling identified the cancer/testis antigen MAGE-A3/6 as a novel target of FGFR2-IIIb signaling. PMID: 17699848
Measurement of Melan-A, gp100, MAGE-3, MIA and tyrosinase represents a prognostic factor and a method for early detection of metastasis and treatment response of melanoma patients. PMID: 18181974
MAGEC1/CT7, MAGEA3/6 and LAGE-1 are good candidates for immunotherapy, since together they cover 85% of our MM cases. PMID: 18237105
the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells are influenced by endosomal proteases PMID: 18316621
MAGE-A3 as a target of FGFR2-IIIb and estrogen action and provide evidence for a common histone-modifying network in the control of the balance between opposing signals. PMID: 18381936
MAGE-A3 may have a role in melanoma and could be used in a therapeutic vaccine PMID: 18483279
MAGE A3 is a functional integrator of diverse signals, including FGFR2 and FN, to modulate cancer progression. PMID: 18829569
Its expression is significantly associated with prognostic factors in poor outcome of the non-small cell lung cancer PMID: 18982744

Hide All

Tissue Specificity

Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes and placenta. Never expressed in kidney tumors, Leukemias and lymphomas.

Database Links

HGNC: 6801

OMIM: 300174

KEGG: hsa:4102

STRING: 9606.ENSP00000359301

UniGene: Hs.417816

Code	CSB-EP013329HU
Abbreviation	Recombinant Human MAGEA3 protein
MSDS	MSDS Datasheet
Size	US$256
	Order now
Image	(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
Have Questions?	Leave a Message or Start an on-line Chat

Recombinant Human Melanoma-associated antigen 3 (MAGEA3)

Product Details

Citations

Related Products

Customer Reviews and Q&A

Target Background

×CloseMessage